<DOC>
	<DOCNO>NCT00005964</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one chemotherapy drug may kill tumor cell . It yet know combination chemotherapy regimen effective treat aggressive non-Hodgkin 's lymphoma . PURPOSE : Randomized phase II trial compare effectiveness two combination chemotherapy regimens treat patient previously untreated aggressive stage II , stage III , stage IV non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Comparison Two Combination Chemotherapy Regimens Treating Patients With Previously Untreated Aggressive Stage II , Stage III , Stage IV Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient previously untreated aggressive non-Hodgkin 's lymphoma treat doxorubicin , etoposide , vincristine , cyclophosphamide , prednisone ( EPOCH ) . II . Determine toxic effect regimen patient . OUTLINE : This multicenter study . Patients receive doxorubicin IV , etoposide IV , vincristine IV , cyclophosphamide IV continuously day 1-4 . Patients also receive oral prednisone twice daily day 1-5 filgrastim ( G-CSF ) subcutaneously begin day 6 blood count recover . Treatment continue every 21 day maximum 8 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage II , III , IV nonHodgkin 's lymphoma ( NHL ) Diffuse large Bcell lymphoma ( include immunoblastic feature ) OR Anaplastic large cell lymphoma No mantle cell lymphoma include equivocal Bcell lymphoma CD5+ CD23 , ( 11 ; 14 ) , express marker mantle cell lymphoma subtypes No lowgrade lymphoma ( e.g. , follicular center cell bone marrow ) Patients 35 International Prognostic Index risk factor must refuse participation SWOGS9704/CALGB59903 trial No known lymphomatous CNS involvement , include parenchymal leptomeningeal involvement PATIENT CHARACTERISTICS : Age : Not specify Performance status : 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3* Platelet count least 100,000/mm3* *unless attributable NHL Hepatic : Bilirubin great 2.0 mg/dL ( without Gilbert 's disease ) * *unless attributable NHL Renal : Creatinine great 1.5 mg/dL* *unless attributable NHL Cardiovascular : LVEF great 45 % No ischemic heart disease No myocardial infarction congestive heart failure past year Other : Not pregnant nursing Fertile patient must use effective contraception HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytotoxic chemotherapy No concurrent chemotherapy Endocrine therapy : Prior glucocorticoid allow ( less 10 day course ) urgent local disease diagnosis ( e.g. , cord compression , superior vena cava syndrome ) No concurrent dexamethasone ( except indicate protocol ) steroidal antiemetics No concurrent hormonal therapy except nondisease related condition Radiotherapy : Prior limited field radiotherapy allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
</DOC>